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Abstract: BACKGROUND AIMS Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder.
Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it is
not clear if these drugs are effective for long-term maintenance of remission. METHODS We performed
a double-blind trial to compare the efficacy and safety of 2 doses of a budesonide orodispersible tablet
(BOT) vs placebo in maintaining remission of EoE. Maintenance of remission was defined as absence of
clinical and histological relapse and no premature withdrawal for any reason. Two hundred and four adults
with EoE in clinical and histologic remission, from 29 European study sites, were randomly assigned to
groups given BOT 0.5 mg twice daily (n=68), BOT 1.0 mg twice daily (n=68), or placebo twice daily
(n=68) for up to 48 weeks. RESULTS At end of treatment, 73.5% of patients receiving BOT 0.5 mg
twice daily and 75% receiving BOT 1.0 mg twice daily were in persistent remission, compared with 4.4%
of patients in the placebo group (P<.001 for both comparisons of BOT with placebo). Median time
to relapse in the placebo group was 87 days. The frequency of adverse events was similar in the BOT
and placebo groups. Morning serum levels of cortisol were in the normal range at baseline and did not
significantly change during treatment. Four patients receiving BOT developed asymptomatic, low serum
levels of cortisol. Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5
mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment.
CONCLUSIONS In a phase 3 trial, up to 48 weeks of treatment with BOT (.5 mg or 1.0 mg, twice daily)
was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well
tolerated. (Funded by Dr. Falk Pharma GmbH; EudraCT number; 2014-001485-99; ClinicalTrials.gov
number, NCT02434029.).
DOI: https://doi.org/10.1053/j.gastro.2020.07.039
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BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is a
chronic inflammatory disorder. Swallowed topical-acting cor-
ticosteroids are effective in bringing active EoE into remission.
However, it is not clear whether these drugs are effective for
long-term maintenance of remission. METHODS: We per-
formed a double-blind trial to compare the efficacy and safety
of 2 dosages of a budesonide orodispersible tablet (BOT) vs
placebo in maintaining remission of EoE. Maintenance of
remission was defined as absence of clinical and histologic
relapse and no premature withdrawal for any reason. Two
hundred and four adults with EoE in clinical and histologic
remission, from 29 European study sites, were randomly
assigned to groups given BOT 0.5 mg twice daily (n ¼ Q868), BOT
1.0 mg twice daily (n ¼ 68), or placebo twice daily (n ¼ 68) for


































































































































up to 48 weeks. RESULTS: At end of treatment, 73.5% of
patients receiving BOT 0.5 mg twice daily and 75% receiving
BOT 1.0 mg twice daily were in persistent remission
compared with 4.4% of patients in the placebo group (P <
.001 for both comparisons of BOT with placebo). Median time
to relapse in the placebo group was 87 days. The frequency of
adverse events was similar in the BOT and placebo groups.
Morning serum levels of cortisol were in the normal range at
baseline and did not significantly change during treatment.
Four patients receiving BOT developed asymptomatic, low
serum levels of cortisol. Clinically manifested candidiasis was
suspected in 16.2% of patients in the BOT 0.5 mg group and
in 11.8% of patients in the BOT 1.0 mg group; all infections
resolved with treatment. CONCLUSIONS: In a phase 3 trial, up
to 48 weeks of treatment with BOT (0.5 mg or 1.0 mg twice
daily) was superior to placebo in maintaining remission of EoE.
Both dosages were equally effective and well tolerated.
EudraCT number; 2014-001485-99; ClinicalTrials.gov number,
NCT02434029.
Keywords: Topical Corticosteroids; Dysphagia; Remission; Pa-
tient-Reported Outcomes.
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, esophageal-restricted disease, character-
ized clinically by symptoms of esophageal dysfunction and
histologically by an eosinophil-predominant inflamma-
tion.1,2 Dramatic increases in incidence and prevalence of
EoE have been documented during the last 2 decades.3–5
EoE is currently the most common cause of esophageal
dysphagia and food bolus impaction.6 Long-standing eosin-
ophilic inflammation leads to esophageal remodeling in EoE,
resulting in fibrosis with stricture formation and functional
damage.7–10 Consequently, EoE negatively impacts on the
health-related quality of life (HRQoL) of patients by causing
emotional distress and restricting social activities.11 An
active EoE is therefore a clear indication to treat these
patients.12
The efficacy of swallowed topical corticosteroids (STC),
such as budesonide or fluticasone, to improve symptoms
and inflammation in patients with EoE has been confirmed
in multiple trials,13 placing STCs as a first-line medical
therapy for active disease.2 However, original formulations
of these drugs developed for airway administration in
asthma,14,15 until now used off-label in EoE, resulted in
suboptimal esophageal targeting and efficacy. Results from a
phase 3 trial showed the effectiveness of a 6-week treat-
ment with new budesonide orodispersible tablet (BOT) to
induce clinicohistologic remission in 58% of adult patients
with EoE, which increased to 85% when therapy was
extended to 12 weeks in nonresponders.16 Because EoE is a
chronic condition17 and the vast majority of patients expe-
rience a relapse rapidly after discontinuation of treatment,18
long-term management is required. However, confirmatory
maintenance trials with STCs are missing.
In this study, we evaluated the efficacy and safety of this




This phase 3, randomized, double-blind, placebo-controlled,
multicenter, 48-week maintenance trial was conducted at 37
medical centers in 6 European countries (Supplementary
Table 1) from January 2016 to November 2018. The protocol
was approved by the national ethics committees in all partici-
pating countries. All patients provided written informed con-
sent. The study was conducted and reported in accordance with
the protocol.
Study Population
Eligible patients were 18–75 years of age with previously
confirmed diagnosis of proton pump inhibitor (PPI)-refractory
EoE according to established criteria1,2 and in confirmed clin-
icohistologic remission at baseline after achieving study goals
of a double-blind controlled induction treatment study (EOS-1)
with BOT 1.0 mg twice daily,16 or by receiving open-label in-
duction with BOT 1.0 mg twice daily for 6 weeks. Patients from
either route of entry had to be enrolled via the same inclusion
and exclusion criteria to enter the induction of clinicohistologic
remission phase. Therefore, patients from both entry routes
showed similar demographic and disease-specific characteris-
tics. Clinical remission was defined as a severity of 2 points Q9
on 1- to 10-point numerical rating scale (NRS) for dysphagia
and a severity of 2 points on a 0- to 10-point NRS for ody-
nophagia on each day in the last week of induction treatment.
Histologic remission was defined as peak eosinophil count <16
eosinophils (eos)/mm2 high-power field (hpf; 400; corre-
sponding to <5 eos/hpf as reported previously15,16,19) at
baseline endoscopy, measured in hpf derived from 6 biopsies, 2
of each esophageal third. Patients were ineligible if there was a
clinical and endoscopic suspicion for gastroesophageal reflux
disease; achalasia or scleroderma; evidence of reasons for
esophageal eosinophilia other than EoE; pathologic eosinophilic
infiltration in gastric and duodenal biopsies; history of esoph-
ageal surgery at any time or of esophageal dilation procedures
within the last 8 weeks before induction treatment; or any
relevant systemic disease.
Randomization and Study Intervention
Included patients were randomly assigned, in a 1:1:1 ratio,
to receive BOT 0.5 mg twice daily (Jorveza Q100.5 mg orodisper-
sible tablets; Dr Falk Pharma GmbH, Freiburg, Germany), BOT
1.0 mg twice daily (Jorveza 1 mg orodispersible tablets; Dr Falk
Pharma GmbH) or placebo, using an Interactive Web Response
* Authors share co-first authorship.
Abbreviations used in this paper: AE, adverse event; BOT, budesonide
orodispersible tablet; CI, confidence interval; EoE, eosinophilic esopha-
gitis; EoE-QoL-A, Eosinophilic Esophagitis Quality of Life Scale for Adults;
eos/hpf, eosinophils per high-power field; EoT, end of treatment; EREFS,
Endoscopic Reference Score; HRQoL, health-related quality of life; NRS,
numerical rating scale; PPI, proton pump inhibitor; STC, swallowed
topical-acting corticosteroids.
© 2020 by the AGA Institute. Published by Elsevier Inc. This is an open
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System and a computer-generated list of sequentially random
numbers with randomly permuted block size of 6. Allocation
concealment was ensured as patients, investigators and their
study team, the sponsor, monitoring staff, central laboratory,
and central pathologist, were all kept blinded to the randomi-
zation sequence, block size, and patient’s treatment, until all
patients had completed the study and the database was clean
and locked. No individual unblinding was needed or performed.
At baseline and at each of the interim visits, patients
received study medication for the next period. BOT 0.5 mg, 1.0
mg, and placebo tablets were identical in physical appearance
and taste. BOT and placebo were administered twice daily. The
orodispersible tablet was placed on the tip of the tongue and
pressed gently against the hard palate until it had completely
disintegrated by contact with saliva, the production of which
was stimulated by the effervescence properties of the study
medication. The components dissolved in saliva were then
continuously swallowed (approximately 10 swallows within
several minutes). Patients were instructed to avoid eating,
drinking, or oral hygiene procedures for 30 minutes after study
drug administration. Compliance was assessed at each study
visit by pill count; patients who returned less than two-thirds of
the distributed study medication or having an adherence to
treatment of <70% were assessed as being noncompliant and
were excluded from the per-protocol analysis. The use of other
STCs, systemic glucocorticoids, immunosuppressants, biologic
drugs, or onset of dietary restrictions was not permitted.
Concomitant PPI treatment was to be kept stable.
Evaluation of Efficacy and Safety
Post-randomization interim visits took place at weeks 4, 12,
24, 36, and 48. In addition, telephone interviews were con-
ducted at 4-week intervals in-between clinical visits.
Symptoms (dysphagia and odynophagia) and Patient’s
Global Assessment of EoE activity were assessed at each visit
using 0–10 NRS (higher scores indicating more severe symp-
toms or disease activity). The use of a simple clinical readout
instrument with an obvious face validity such as NRS was
suggested by Scientific Protocol Advice from the European
Medicines Agency.Q11 Validated Eosinophilic Esophagitis Activity
Index–Patient Reported Outcome score (range, 0–100 points)
was completed at every visit (higher scores indicating more
severe disease activity).20 Validated Eosinophilic Esophagitis
Quality of Life Scale for Adults (EoE-QoL-A) questionnaire
version 2.0 (licensed from Northwestern University, Evanston,
IL) was completed at weeks 0, 24, and 48 (range 0–4 points;
with higher scores indicating better HRQoL).21,22
Upper endoscopy was performed at baseline and end of
treatment (EoT) or in case of patient’s premature withdrawal.
Esophageal findings were classified according to the validated
modified Endoscopic Reference Score (EREFS) grading system
(range, 0–9 points; with higher scores indicating more severe
endoscopic findings).23 In addition, a global assessment of
endoscopic EoE activity was performed and classified as
“none,” “mild,” “moderate,” or “severe.”
At each endoscopy, 2 biopsies of each esophageal third
were obtained and analyzed blindly. Biopsy specimens were
fixed in 4% neutral-buffered formalin and embedded in
paraffin. On each H&E-stained esophageal biopsy specimen, all
levels were surveyed and the eosinophils in the most densely
infiltrated area were counted (hpf area of 0.345 mm2) and
reported as eos/mm2 hpf. In patients with clinically, endo-
scopically, or histologically suspected local fungal infection.
Grocott silver staining was performed on esophageal biopsy
specimen for final confirmation.
Physical examinations were performed during screening
and at EoT visits. During all interim visits, vital signs,
concomitant medications, and adverse events were assessed
and general laboratory tests were performed. Serum morning
cortisol (8:00 AM to 9:00 AM) levels were measured at baseline
and EoT visits. Tolerability was classified by the patient and the
investigator independently at the EoT. Regular eye examina-
tions were performed to check for cataract and glaucoma.
Outcomes
The primary outcome was remission at week 48, that is,
rate of patients fulfilling none of the following criteria: clinical
relapse (ie, dysphagia or odynophagia [7-day recall period]
with severity 4 points, confirmed by 4 points on at least 1
day during the subsequent week on the respective 0–10 point
NRS for dysphagia or odynophagia [24-hours recall period]);
histologic relapse (ie, peak of 48 eos/mm2 hpf [corresponding
to 15 eos/hpf15] at EoT; food impaction requiring endoscopic
intervention; need for dilation; or premature withdrawal for
any reasons.
A priori–ordered secondary outcomes at week 48 included
rate of histologic relapse (as defined above); change in the peak
eos/mm2 hpf from baseline to EoT; rate of clinical relapse (as
defined above); food impaction that required endoscopic
intervention or endoscopic dilation; rate of clinical remission
(Eosinophilic Esophagitis Activity Index–Patient Reported
Outcome score 20).
Exploratory outcomes were change from baseline in the
Patient’s Global Assessment of EoE activity; time to clinical
relapse; deep histologic remission (0 eos/mm2 hpf); changes in
endoscopic alterations; deep endoscopic remission (0 points
total EREFS score); and HRQoL and patient’s global satisfaction
with treatment.
As a post-hoc analysis, the rate of patients in clinicohisto-
logic remission, as defined at baseline, was assessed at week
48/EoT.
Study Oversight
The study was designed and implemented by members of
the EOS-2 protocol review board (A. Straumann, A.J.L., S.M., A.
Schoepfer) and researchers employed by Dr Falk Pharma (R.M.,
R.G.). Data were collected and analyzed by a contract research
organization. The first draft manuscript was written by A.
Straumann; all authors had access to the study data and
reviewed and approved the final manuscript.
Statistical Analyses
Assuming relapse/treatment failure rates of 50%, 30%, and
25% with placebo, BOT 0.5 mg twice daily, and BOT 1.0 mg
twice daily, respectively, simulations with ADDPLAN, version
6.0 (ICON Clinical Research, Dublin, Ireland) showed that a
total of 192 intention-to-treat patients were needed using the
normal approximation test for rates based on 1-sided a ¼ .025
with a statistical power of at least 80%. Sample size was
increased for 5% of randomized patients who might not have
Q1- 2020 Maintaining Remission of EoE With Budesonide 3

































































































































taken at least 1 dose of the study drug, and in total 204 patients
were to be randomized.
The primary efficacy variable and the dichotomous a priori–
ordered secondary efficacy variables were confirmatory tested
(1-sided, with the intent to show the superiority of active
treatment over placebo) separately for both BOT arms vs pla-
cebo at Bonferroni adjusted significance levels of .0125, using
the normal approximation tests for the comparison of rates.
Two-sided 97.5% (Bonferroni correction) confidence intervals
(CIs) for the difference of rates were provided. Efficacy signif-
icance testing continued in hierarchical fashion for the sec-
ondary end points. Once a 1-sided nonsignificant P value (P >
.0125) occurred, subsequent significance tests were considered
exploratory. Change in peak eos/mm2 hpf was analyzed using
the Wilcoxon rank sum test also at Bonferroni-adjusted sig-
nificance level of .0125.
Analyses of exploratory end points between treatment
groups or between baseline and EoT were performed using
2-sided t tests or Wilcoxon rank-sum tests, as appropriate.
Two-sided Fisher exact test was applied to dichotomous data.
Time-to-event variables were described using Kaplan-Meier
methods. Descriptive statistics were used to summarize data.
Adverse events were classified using the Medical Dictionary
for Regulatory Activities, version 19.24
Analyses were performed using SAS, version 9.3 (SAS
Institute, Cary, NC) and according to the intention-to-treat
principle. Missing data at week 48 were not replaced, in such
case a treatment failure was assumed.
Results
Patient Flow and Baseline Characteristics
From a total of 269 patients treated with BOT 1.0 mg
twice daily for 6–12 weeks for induction of remission, 204
came into clinicohistologic remission, fulfilling the inclusion
criteria for the double-blind phase, and were randomized
for 48-week maintenance treatment into 3 groups (BOT 0.5
mg twice daily, BOT 1.0 mg twice daily, and placebo twice
daily) of identical size of 68 patients, each. In total, 141
patients completed the double-blind phase (69.1%), but all
204 patients were evaluable for the primary analysis
(Supplementary Figure 1).
All 3 treatment groups had similar demographic and
disease-specific characteristics at baseline of the mainte-
nance phase, in particular the rate of concomitant PPI
treatment in all of the treatment groups was the same
(Table 1). Baseline characteristics before the initial acute
therapy for induction of clinicohistologic remission were
also similar between the treatment groups (see
Supplementary Table 2).
Efficacy
The primary outcome—number of patients in remission
after a 48-week maintenance treatment—was achieved in
50 of 68 (73.5%; P < .001), 51 of 68 (75.0%; P < .001), and
3 of 68 (4.4%) patients in the BOT 0.5 mg twice daily, BOT
1.0 mg twice daily, and placebo groups, respectively
(Table 2, Figure 1A). The efficacy of BOT was generally
consistent across subgroups and the results were not
significantly influenced by baseline conditions (ie, history of
allergic diseases, localization of inflammation at baseline of
induction treatment, or concomitant PPI use; see
Supplementary Table 3). However, remission rates under
BOT 1.0 mg twice daily were clinically relevant higher
compared with BOT 0.5 mg twice daily in patients with an
extended inflammation (ie, all 3 esophageal segments were
affected; 80% vs 68%) at baseline of their induction treat-
ment and for patients with a longstanding disease history
(ie, 9 years or longer; see Supplementary Table 3). The time
to clinical relapses during the 48-week study period in the 3
treatment groups is illustrated in Figure 2.
All secondary efficacy outcomes proved superiority of
BOT 0.5 mg twice daily and BOT 1.0 mg twice daily over
placebo in a confirmatory manner: Rates of patients expe-
riencing a histologic relapse were 9 of 68 (13.2%; P < .001),
7 of 68 (10.3%; P < .001), and 61 of 68 (89.7%) in the BOT
0.5 mg twice daily, BOT 1.0 mg twice daily, and placebo
group, respectively. Clinical relapses occurred in 7 of 68
(10.3%, P < .001), 5 of 68 (7.4%; P < .001), and 41 of 68
(60.3%) in the 3 treatment groups (Table 2). In a post-hoc
assessment, clinicohistologic remission, as defined at base-
line, was in line with the primary end point and was ach-
ieved in 48 of 68 (70.6%; P < .001), 50 of 68 (73.5%; P <
.001), and 1 of 68 (1.5%) patients in the BOT 0.5 mg twice
daily, BOT 1.0 mg twice daily, and placebo group, respec-
tively (Table 2). Histologic remission in the BOT 0.5 and 1.0
mg twice daily group was independently maintained in all
esophageal segments (data not presented).
The rates of endoscopic remission decreased under BOT
0.5 mg twice daily slightly from 74% at baseline to 68% at
week 48 (P ¼ .670), increased with BOT 1.0 mg twice daily
from 66% to 74% (P ¼ .127), but dropped significantly with
placebo during the study period from 63% to 7% (P <
.001). Baseline total modified EREFS score was low in all
treatment groups and comparable with a mean of 1 point at
baseline (Table 2), as well as in later remitters or non-
remitters (Supplementary Table 4). Interestingly, treatment
failures with placebo also showed a substantial change in
total modified EREFS score (mean change, 3; 95% CI, 2.7 to
3.6; P < .001), due mainly to an increase of the inflamma-
tory subscore, whereas treatment failures with BOT 0.5 mg
twice daily and BOT 1 mg twice daily had only a small and
not significant increase in total modified EREFS score of 1
(95% CI, –0.2 to 1.6; P ¼ .148) and 1 (95% CI, –0.1 to 1.6;
P ¼ .125) (Supplementary Table 4). In contrast, clin-
icohistologic remitters with BOT 1 mg twice daily treatment
showed even further significant improvement in their total
modified EREFS score (–0; 95% CI, –0.7 to –0.2; P < .001;
Supplementary Table 4).
HRQoL overall and its subscores (eating and diet impact,
social impact, emotional impact, disease anxiety, and swal-
lowing anxiety) improved significantly from baseline to EoT
in both BOT groups, whereas a significant deterioration in
HRQoL was detected in the total EoE-QoL-A and most of its
subscores after placebo treatment. The intragroup com-
parison (BOT vs placebo) of the mean changes from baseline
to EoT was also significant for both BOT dosage groups
(Table 2).
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Age, y, mean ± SD 36 ± 10.9 37 ± 11.1 36 ± 9.9 36 ± 10.6
Male sex, n (%) 57 (83.8) 57 (83.8) 55 (80.9) 169 (82.8)
White race,a n (%) 68 (100.0) 68 (100) 68 (100.0) 204 (100.0)
Body weight, kg, mean ± SD (n) 76.0 ± 11.6 (67) 79.7 ± 14.2 (67) 76.8 ± 15.2 (67) 77.5 ± 13.8 (201)
Time since first EoE symptoms, y, mean ± SD 12.6 ± 8.5 11.8 ± 9.4 9.6 ± 8.2 11.4 ± 8.8
Time since EoE diagnosis, y, mean ± SD 4.3 ± 3.5 4.2 ± 4.0 3.3 ± 2.9 3.9 ± 3.5
History of esophageal dilation, n (%) 13 (19.1) 8 (11.8) 4 (5.9) 25 (12.3)
History of allergic disease, n (%) 54 (79.4) 55 (80.9) 50 (73.5) 159 (77.9)
History of having experienced, n (%)
Dysphagia 68 (100.0) 66 (97.1) 68 (100.0) 202 (99.0)
Odynophagia 42 (61.8) 40 (58.8) 41 (60.3) 123 (60.3)
Food impaction (with or without endoscopic removal) 65 (95.6) 59 (86.8) 61 (89.7) 185 (90.7)
Concomitant treatment with PPI, n (%) 16 (23.5) 12 (17.6) 9 (13.2) 37 (18.1)
Daily dysphagia NRS last 7 d,b mean ± SD 1 ± 0.9 1 ± 0.9 1 ± 0.8 1 ± 0.9
Daily odynophagia NRS last 7 d,b mean ± SD 1 ± 0.9 1 ± 1.0 0 ± 0.8 1 ± 0.9
EEsAI-PRO,c mean ± SD 16 ± 14.1 16 ± 15.8 16 ± 15.8 18 ± 16.6
EEsAI-PRO 20 points,c n (%) 43 (63.2) 46 (67.6) 38 (55.9) 127 (62.3)
PatGA,d mean ± SD 1 ± 0.8 1 ± 0.8 1 ± 0.9 1 ± 0.8
EoE-QoL-A 30 items weighted questionnaire,e mean ± SD 3.2 ± 0.6 3.2 ± 0.6 3.0 ± 0.7 3.1 ± 0.6
Overall peak eos/mm2 hpf,f mean ± SD 0 ± 1.4 0 ± 1.7 1 ± 3.6 0 ± 2.4
Deep histologic remission (0 eos/mm2 hpf),f n (%) 65 (95.6) 68 (95.6) 64 (94.1) 194 (95.1)
Total modified EREFS score (0–9 points),g mean ± SD 1 ± 1.1 1 ± 1.1 1 ± 1.0 1 ± 1.0
Inflammatory signs subscore (0–4 points) 0 ± 0.6 0 ± 0.6 0 ± 0.6 0 ± 0.6
Fibrotic signs subscore (0–4 points) 1 ± 0.7 0 ± 0.6 0 ± 0.6 0 ± 0.6
Inflammatory remission, all inflammatory grades 0, n (%) 48 (70.6) 49 (72.1) 49 (72.1) 146 (71.6)
Complete remission, all grades 0, n (%) 34 (50.0) 34 (50.0) 35 (51.5) 103 (50.5)
Endoscopist Global Assessment
No signs of EoE, n (%) 50 (73.5) 45 (66.2) 43 (63.2) 138 (67.6)
Moderate or severe signs of EoE, n (%) 1 (1.5) 2 (2.9) 1 (1.5) 4 (2.0)
BID, twice daily; EEsAI-PRO, Eosinophilic Esophagitis Activity Index Patient Reported Outcome; PatGA, Patient’s Global
Assessment of EoE activity.
aRace was self-reported.
bNRS for dysphagia and odynophagia, respectively, ranging from 0 to 10 points; higher scores indicating greater symptom
severity.
cEEsAI-PRO score ranging from 0 to 100 points with higher scores indicating greater disease severity; clinical remission is
defined as a score of 20 points.
dPatGA is an NRS ranging from 0 to 10 points; higher scores indicating greater disease activity.
eEoE-QoL-A questionnaire, version 2.0, is a validated 24-item scale with a 6-questions addendum for those on elimination diet
therapies, to measure HRQoL for adult patients with EoE, in which every item is scored from 0 (very poor HRQoL) to 4 (very
good HRQoL).
fPeak eosinophils count standardized to mm2 hpf (400). Peak of <16 eos/mm2 hpf in all 6 biopsies, 2 each derived from the
derived proximal, mid, and distal esophagus, was defined as histologic remission; 0 eos/mm2 hpf in all biopsies was deep
histologic remission.
gModified EREFS grading system summing the scores of the 5 major features (edema [0–1], rings [0–3], exudates [0–2], furrows
[0–1], strictures [0–1]) and 1 minor (crêpe paper esophagus [0–1]); total score ranged from 0 to 9 points, with higher score
indicating more severe endoscopic findings. Inflammatory subscore (edema [0–1], exudates [0–2], furrows [0–1]), ranged from
0 to 4 points, with higher score indicating more severe inflammatory findings; Fibrotic subscore (rings [0–3], strictures [0–1]),
ranged from 0 to 4 points, with higher score indicating more severe fibrotic findings.
- 2020 Maintaining Remission of EoE With Budesonide 5

































































































































Table 2. Q16Efficacy of Maintenance Treatment of Eosinophilic Esophagitis With Orodispersible Budesonide Tablets
Outcome variable
BOT 0.5 mg
BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo BID,













Maintaining remission, n/N (%) 50/68 (73.5) 51/68 (75.0) 3/68 (4.4) 69.1 (55.9 to
82.3)
.001b 70.6 (57.6 to
83.6)
.001b
A priori–ordered secondary outcomes
Histologic relapse (48 eos/mm2 hpf at EoT),c n/N (%) 9/68 (13.2) 7/68 (10.3) 61/68 (89.7) –76.5 (–88.8 to
–64.1)
.001b –79.4 (–91.1 to
–67.7)
.001b
Change in peak eos/mm2 hpf from baseline to EoT,c







ND .001d ND .001d
Clinical relapse, food impaction needing endoscopic
intervention, or need for dilation (multiple reasons possible),
n/N (%)
7/68 (10.3) 5/68 (7.4) 41/68 (60.3) –50.0 (–65.7 to
–34.3)
.001b –52.9 (–68.0 to
–37.9)
.001b
Clinical relapse 7/68 (10.3) 5/68 (7.4) 41/68 (60.3)
Food impaction needing endoscopic intervention 0/68 (0) 0/68 (0) 1/68 (1.5)
Need for dilation 0/68 (0) 0/68 (0) 0/68 (0)
Weekly EEsAI-PRO (0–100) score of 20 at EoT,e n/N (%) 49/68 (72.1) 50/68 (73.5) 14/68 (20.6) 51.5 (35.1 to
67.9)





BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo BID,













Maintaining clinicohistologic remission at EoT
(dysphagia NRS [0–10] and odynophagia NRS
[0–10] both 2 points in the last week before EoT
and <16 eos/mm2 hpf at EoT), n/N (%)
48/68 (70.6) 50/68 (73.5) 1/68 (1.5) 69.1 (57.9 to
80.3)


























































































































































































































































































































































































































































BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo BID,













PatGA (0–10) at EoT,f mean ± SD (n) 1 ± 1.8 (66) 1 ± 1.7 (67) 4 ± 2.6 (64) ND .001g ND .001g
Absolute change from baseline to EoT, f
mean ± SD (n)
–0 ± 2.0 (66) –0 ± 1.8 (67) 3 ± 2.7 (63) ND .001g ND .001g
PatGA 2 at EoT,f n/N (%) 60/68 (88.2) 58/69 (85.3) 22/68 (32.4) 55.9 (42.4 to
69.4)
.001h 52.9 (39.0 to
66.9)
.001h
Dysphagia NRS (0–10) change from baseline to EoT,i
mean ± SD (n)
0 ± 2.0 (66) 0 ± 1.8 (67) 3 ± 2.9 (65) ND .001g ND .001g
Odynophagia NRS (0–10) change from baseline to
EoT,i mean ± SD (n)
0 ± 1.8 (66) –0 ± 1.6 (67) 2 ± 2.7 (65) ND .001g ND .001g
EEsAI-PRO at EoT, e mean ± SD (n) 14 ± 18.5 (65) 11 ± 18.0 (66) 39 ± 21.4 (65) ND .001g ND .001g
Absolute change from baseline to EoT in EEsAI-
PRO, mean ± SD (n)e
–2 ± 19.2 (64) –7 ± 18.1 (65) 22 ± 23.1 (65) ND .001g ND .001g
Histologic
Histologic remission (<16 eos/mm2 hpf at EoT),c
n/N (%)
53/68 (77.9) 57/68 (83.8) 2/68 (2.9) 75.0 (64.4 to 85.6) .001h 80.9 (71.3 to 90.5) .001h
Deep histologic remission (0 eos/mm2 hpf at EoT),c
n/N (%)
52/68 (76.5) 54/68 (79.4) 1/68 (1.5) 75.0 (64.5 to 85.5) .001h 77.9 (67.9 to 88.0) .001h
Maintaining deep histologic remission (0 eos/mm2
hpf) from baseline to EoT,c n/N (%)
50/65 (76.9) 51/65 (78.5) 1/64 (1.6) 75.4 (64.9 to 86.0) .001h 76.9 (66.5 to 87.3) .001h
Endoscopic
Total modified EREFS score (0–9 points) at EoT,j
mean ± SD (n)
1 ± 1.2 (65) 1 ± 1.1 (65) 4 ± 1.8 (65) ND .001g ND .001g
Absolute change from baseline to EoT in total
modified EREFS score, j mean ± SD (n)
–0 ± 1.4 (65) –0 ± 1.2 (65) 3 ± 1.9 (65) ND .001g ND .001g
Absolute change from baseline to EoT in
inflammatory signs subscore, j mean ± SD (n)
0 ± 1.0 (65) –0 ± 0.8 (65) 2 ± 1.2 (65) ND .001g ND .001g
Absolute change from baseline to EoT in fibrotic
signs subscore, j mean ± SD (n)
–0 ± 0.7 (65) –0 ± 0.5 (65) 1 ± 1.0 (65) ND .001g ND .001g
Complete remission (all grades 0) at EoT, j n/N (%) 36/68 (52.9) 39/68 (57.4) 4/68 (5.9) 47.1 (33.9 to 60.2) .001h 51.5 (38.5 to 64.5) .001h
Moderate or severe fixed rings present at EoT,
n/N (%)
4/68 (5.9) 2/68 (2.9) 20/68 (29.4) –23.5 (–35.7 to –11.3) .001h –26.5 (–38.0 to –14.9) .001h
Endoscopist’s assessment, no signs of EoE at EoT,
n/N (%)
46/68 (67.5) 50/68 (73.5) 5/68 (7.4) 60.3 (47.6 to 73.0) .001h 66.2 (54.0 to 78.4) .001h
Endoscopist’s assessment, moderate or severe
signs of EoE at EoT, n/N (%)


























































































































































































































































































































































































































































BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo BID,













EoE-QoL-A 30 items questionnairek




3.0 ± 0.70 (64) ND ND ND ND




2.8 ± 0.75 (65) ND .001g ND .001g








0.46 (0.27 to 0.66) .001g 0.50 (0.30 to 0.70) .001g
Patient’s global satisfaction with treatment at EoT,
extremely satisfied or satisfied,l n/N (%)
62/68 (91.2) 49/68 (94.1) 46/68 (67.6) 23.5 (10.5 to 36.5) .001h 26.5 (14.0 to 38.9) .001h
BID, twice daily; EEsAI-PRO, Eosinophilic Esophagitis Activity Index Patient Reported Outcome; ND, not determined; PatGA, Patient’s Global Assessment of EoE activity.
aBonferroni correction.
bNormal approximation test was used for testing 1-sided P value (a ¼ .0125).
cPeak eosinophils count standardized to mm2 hpf (400). Peak of 48 eos/mm2 hpf (corresponding to 15 eos/hpf) in at least 1 of 6 biopsies (2 each derived from the
proximal, mid, and distal esophagus) was defined as histologic relapse; peak of <16 eos/mm2 hpf (corresponding to <5 eos/hpf15) in all biopsies was histologic remission
and 0 eos/mm2 hpf in all biopsies was deep histologic remission.
dWilcoxon rank-sum test was used for testing 1-sided P value (a ¼ .0125).
eEEsAI-PRO score ranging from 0 to 100 points with higher scores indicating greater disease severity; clinical remission is defined as a score of 20 points.
fPatGA is an NRS ranging from 0 to 10 points; higher scores indicating greater disease activity.
gWilcoxon rank-sum test was used for testing 2-sided P value (a ¼ .025).
hWilcoxon rank-sum test was used for testing 2-sided p-value (a ¼ .025). Normal approximation test was used for testing 2-sided P value (a ¼ .025).
iNRS for dysphagia and odynophagia, respectively, ranging from 0 to 10 points; higher scores indicating greater symptom severity.
jModified EREFS grading system summing the scores of the 5 major features (edema [0–1], rings [0–3], exudates [0–2], furrows [0-1], strictures [0–1]) and 1 minor (crêpe
paper esophagus [0–1]); total score ranged from 0 to 9 points, with higher score indicating more severe endoscopic findings. Inflammatory subscore (edema [0–1], ex-
udates [0–2], furrows [0–1]), ranged from 0 to 4 points, with higher score indicating more severe inflammatory findings; Fibrotic subscore (rings [0–3], strictures [0–1]),
ranged from 0 to 4 points, with higher score indicating more severe fibrotic findings.
kEoE-QoL-A questionnaire, version 2.0, a validated 24-item scale with a 6-questions addendum for those on elimination diet therapies, to measure HRQoL for adult
patients with EoE, in which every item is scored from 0 (very poor HRQoL) to 4 (very good HRQoL).























































































































































































































































































































































































































































Overall, both BOT dosages were well tolerated and no
serious drug-related adverse events (AEs) were reported.
No significant differences were observed among the study
groups in commonly reported AEs, most of them were un-
related to the investigational product. Food impaction
requiring endoscopic intervention occurred in 2 patients
receiving placebo, but in no patients in the 2 BOT groups.
The AE “aggravated condition” was more frequent with
placebo (64.7%) than with BOT 0.5 mg twice daily and BOT
1.0 mg twice daily (16.2%, P < .001 and 11.8%, P < .001,
respectively). The most commonly reported drug-related
AEs were mild to moderate symptoms of local candidiasis,
which were treated easily with antimycotics, with no impact
on daily life activities or need to stop study medication,
recovering rapidly after medical treatment, and suspected in
16.1% and 11.8% of patients who received BOT 0.5 mg
twice daily and BOT 1.0 mg twice daily, respectively. Mean
morning cortisol levels at baseline were 12.1, 11.3, and 10.1
mg/dL in the BOT 0.5 mg twice daily, BOT 1.0 mg twice
daily, and placebo groups, respectively, and did not change
at EoT (12.8, 10.1 and 11.9 mg/dL, respectively). However, a
decrease in serum morning cortisol below the lower limit of
normal (6.2 mg/dL) was observed in 4 patients allocated to
BOT (Table 3). Cataract was observed in only 1 patient
receiving placebo.
Discussion
As EoE represents a chronic disease with a high relapse
rate after cessation of therapy,18 a long-term treatment is
required. In contrast to the well-documented efficacy of
STCs to induce remission of EoE,2,12,13 data on maintenance
treatment are scarce. Our study represents the first multi-
center phase 3 trial analyzing efficacy and safety of long-
term use of BOT, a newly developed, esophageal-targeted
STC, to maintain EoE in clinicohistologic remission. In our
study, BOT 0.5 mg twice daily and BOT 1.0 mg twice daily
were effective and superior to placebo to keep adult pa-
tients with EoE in remission over 1 year with remission
rates of up to 75%. This topic had been addressed so far by
just a single-center controlled trial including a small number










Figure 2. Kaplan-Meier analysis of time to clinical relapse.
Median time to clinical relapse during a 48-week treatment
with either budesonide 1.0 mg orodispersible tablet twice











Figure 1. Primary end point: maintenance of remission. Percentage of patients in remission after 48-week treatment with
budesonide 1.0 mg orodispersible tablet twice daily (BOT 1.0mg BID), BOT 0.5mg BID, or placebo BID. (A) Intention-to-treat
(ITT) analysis. (B) Per-protocol (PP) analysis.
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of 0.5 mg as a watery solution.25 In that study, only 35.7% of
patients maintained histologic remission after 1 year, and
three-quarters of them experienced symptom relapse
despite budesonide.25 Different dosages and formulations
might explain differences in efficacy for the same com-
pound.26 With the newly developed BOT formulation, saliva
is used as a vehicle, which most likely results in a prolonged
deposition of the drug on the esophageal surface. In an
Table 3. Q17Safety of Maintenance Treatment of Eosinophilic Esophagitis With Orodispersible Budesonide Tablets
Variable
BOT 0.5 mg
BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo
BID (n ¼ 68)
Patients with at least 1, n (%)
Treatment-emergent AE 57 (83.8) 59 (86.8) 61 (89.7)
Adverse drug reaction 22 (32.4) 22 (32.4) 3 (4.4)
Serious AEa 3 (4.4) 1 (1.5) —
Cartilage injury 1 (1.5) — —
Upper limb fracture 1 (1.5) — —
Sinusitis 1 (1.5)b — —
Inguinal hernia 1 (1.5)b — —
Skull fracture — 1 (1.5) —
AE leading to withdrawal 7 (10.3) 8 (11.8) 42 (61.8)
Condition aggravated (clinical relapse) 7 (10.3) 5 (7.4)c 41 (60.3)d
Food impaction needing endoscopic intervention — — 2 (2.9)d
Chest pain — 1 (1.5)c —
Retinitis — 1 (1.5) —
Oropharyngeal pain — 1 (1.5) —
Dermatitis allergic — 1 (1.5) —
Esophageal dilation — — 1 (1.5)
Food impaction needing endoscopic intervention — — 2 (2.9)
Food impaction without need for endoscopic intervention — 3 (4.4) —
Patients with adverse drug reactions by system organ class and
preferred term (if of special interest), n (%)
Eye disorders 1 (1.5) 1 (1.5) 1 (1.5)
Cataract nuclear — — 1 (1.5)
Gastrointestinal disorders 5 (7.4) 5 (7.4) —
General disorders and administration site conditions 2 (2.9) 2 (2.9) —
Infections and infestations 12 (17.6) 10 (14.7) 1 (1.5)
Candidiasis overall: 12 (17.6) 9 (13.2) —
Suspected symptomatic candidiasis 11 (16.2) 8 (11.8) —
Histologic confirmed candidiasis 5 (7.4) 2 (2.9) —
Histologic confirmed and symptomatic candidiasis 4 (5.9) 1 (1.5) —
Investigations 3 (4.4) 2 (2.9) —
Blood cortisol decreased 2 (2.9)e 2 (2.9)f —
Neoplasms benign, malignant and unspecified — 1 (1.5) —
Lipoma — 1 (1.5) —
Nervous system disorders 3 (4.4) 3 (4.4) —
Dysgeusia — 1 (1.5) —
Reproductive system and breast disorders — 1 (1.5) 1 (1.5)
Respiratory, thoracic and mediastinal disorders — 1 (1.5) —
Skin and subcutaneous tissue disorders 1 (1.5) 3 (4.4) —
Vascular disorders — 1 (1.5) —
Hypertension — 1 (1.5) —
Morning (8:00 AM to 9 AM) serum cortisol, mg/dL
Baseline, mean ± SD (n) 12.1 ± 4.91 (45) 11.3 ± 4.81 (54) 10.1 ± 5.33 (50)
Week 48/EoT, mean ± SD (n) 12.8 ± 6.15 (54) 10.1 ± 4.53 (60) 11.9 ± 5.87 (55)
Absolute change from baseline to week 48/EoT, mean
(95% CI); n
0.5 (–0.36 to 1.44); 45 –1.1 (–2.42 to 0.24); 54 1.7 (0.57 to 2.81); 50
aAll serious AEs were assessed by the investigators as being not related to study drug intake.
bSinusitis and inguinal hernia were reported in the same patient.
cChest pain and clinical relapse were reported in the same patient.
dFood impaction needing endoscopic intervention and clinical relapse were reported in the same patient.
eBoth without clinical symptoms of adrenal insufficiency, values normalized without change in the medication.
fBoth without clinical symptoms of adrenal insufficiency; one value normalized and one was still ongoing without change in the
medication.
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additional prospective observational pediatric study that
assessed long-term remission of EoE,27 a daily dosage of
440 mg fluticasone propionate in an aerosolized formulation
was used for a mean duration of 1.7 years. Despite a re-
ported 30% relapse rate (13 of 43 patients), differences in
study design, population, and compounds and formulations
prevent comparison with our data.
As EoE is defined as a clinicohistologic syndrome1,2,28 in
which clinical manifestations and pathologic data should not
be interpreted in isolation, a combined primary efficacy
outcome was used in this trial. Our primary outcome con-
sisted of both the absence of symptom recurrence and the
lack of eosinophilic inflammation in the esophageal mucosa
at EoT.
Our data demonstrate that 0.5 mg twice daily and 1.0 mg
twice daily BOT were highly efficient in maintaining EoE in
clinicohistologic remission. Overall, almost three-quarters of
patients maintain EoE in remission in regard to symptoms
and inflammatory activity during the whole 48-week study
period, irrespective of the dose used (73.5% receiving BOT
0.5 mg twice daily and 75.0% receiving BOT 1.0 mg twice
daily) and irrespective of the inflammatory activity (0 eos/
mm2 vs 1–15 eos/mm2) at baseline. In contrast, patients in
the placebo group relapsed in >95% during this period.
Accordingly, “aggravation of disease” was the most common
reported AE in 64.7% of patients receiving placebo. These
findings illustrate, firstly, the effectiveness of BOT for the
maintenance treatment of EoE and, secondly, that EoE requires
a proper long-term anti-inflammatory therapy because,
without active treatment, the vast majority of patients expe-
rience a relapse within the first 100 days after cessation of the
medication. Relapse rates in patients treated with BOT did not
increase throughout the whole study period, suggesting that, in
contrast to a retrospective analysis performed in adult patients
with EoE,29 and clearly different from inflammatory bowel
diseases, loss of efficacy over time is likely not a concern for
budesonide used in EoE.
Histologic improvement of EoE is directly related to the
mucosal contact time of the active component,26 which
highlights the importance of using appropriate drug for-
mulations that optimize esophageal targeting, as demon-
strated in the induction trials with BOT.16,19 The same
seems to happen for long-term maintenance treatment, as
the active component reached all esophageal segments in
sufficient concentrations to maintain long-term histologic
remission. In addition, an esophageal longitudinal efficiency
gradient for BOT was not observed, as the histologic relapse
rates in the distal esophagus were not higher than in the
proximal part.
As secondary outcomes, we assessed changes in endo-
scopic features of EoE during the study period, which
mirrored the clinicohistologic evolution: endoscopic remis-
sion (no visible features of EoE activity) remained stable
under BOT in around 70% of patients. In contrast, endo-
scopic signs of inflammation relapsed in the vast majority of
the patients taking placebo, with only 7% of the patients
showing no endoscopic features of EoE.
HRQoL (measured with EoE-QoL-A) significantly
improved in all domains with BOT 0.5 mg and 1.0 mg twice
daily, but deteriorated with placebo. Keeping in mind that
all patients started with an already very good QoL, that is, a
mean EoE-QoL-A total score of 3.0–3.2 of maximum 4.0, the
relative 10% improvement and deterioration with active
and placebo, respectively, are clinically relevant. No further
decrease under placebo was to be expected, as patients
were prematurely withdrawn from the double-blind phase
as soon as a suspected clinical relapse was confirmed. Our
findings are in line with previous research that identified
symptom frequency and duration, severity of endoscopic
features, and histologic disease activity as major de-
terminants for HRQoL in adult patients with EoE.11,30,31
So far, no proper dosage-finding maintenance studies
were performed in EoE,12 thus we compared, in this study,
the efficiency of 3 different dosages of BOT. Remission rates
after 48-week treatment were not significantly different, so
it is likely that a twice daily dosing of 0.5 mg might be
sufficient to successfully maintain long-term remission for
the average adult patient with EoE. Additional studies are
needed to confirm this and to evaluate other treatment
schedules, for example, an easier to adhere once per day
regimen, or an intermittent or even on-demand treatment
strategy.
AE rates were comparable among all 3 treatment groups,
most of them were mild and not related to the investiga-
tional product. No serious drug-related AE occurred. Local
fungal infections with Candida occurred in a higher fre-
quency with budesonide. This well-known AE of STCs was
searched systematically regarding localization and clinical
relevance. In addition, clinically, endoscopically, or histo-
logically suspected candidiasis was confirmed using Grocott
staining in esophageal biopsies.
Overall, the rates of suspected symptomatic Candida
infections appears not to be dose-dependent, with 16.1%
and 11.8% in the 0.5 mg and 1.0 mg twice daily BOT dos-
ages, respectively, and just in the range of previously pub-
lished studies with STCs in EoE.2,12,16,19,32 One explanation
for this finding might be a dose-independent ceiling effect
due to the assumed longstanding contact time of the active
ingredient with this special esophagus-targeted formulation.
The rate of confirmed and symptomatic esophageal candi-
diasis was as low as 5.9% and 1.5% with BOT 0.5 mg twice
daily and 1.0 mg twice daily BOT, respectively, and did not
increase throughout the study period. It was easy to treat
and almost never interfered with the daily life activities of
patients.
BOT is a mainly locally acting corticosteroid, and so far
neither short-term trials performed in adult patients with
EoE nor a study evaluating prolonged use of swallowed
budesonide33 have raised relevant systemic safety concerns.
Despite a phase 1 study with BOT that showed that a small
fraction of budesonide appeared in the systemic circulation in
patients with EoE,34 no clinically relevant reduction in
morning cortisol levels was found among our patients, in-
dependent of the BOT dosage used. However, 4 patients
developed low serum cortisol levels with BOT but without
symptoms of adrenal insufficiency. Nevertheless, we recom-
mend monitoring symptoms and signs of adrenal insuffi-
ciency when administrating topical-acting corticosteroids
- 2020 Maintaining Remission of EoE With Budesonide 11

































































































































over prolonged time periods, in particular in children and
when using higher dosages.
Our study also had some limitations. First, we did not
identify a minimally effective dose regimen to maintain EoE
in remission because the 2 BOT dosages assessed achieved
similar remission rates under the end points evaluated,
which does not preclude that a dosage even lower than 0.5
mg twice daily could still maintain long-term remission of
EoE compared with placebo. However, an extensive sub-
group analysis should be performed to assess potential
prognostic factors for future guidance on which patients
might benefit from a higher maintenance dosage of BOT 1.0
mg twice daily. Second, concomitant treatment with PPIs at
stable dosages was allowed along the trial, which could have
contributed to the lack of symptoms at EoT in a proportion
of patients with placebo. Finally, we did not measure, sys-
tematically, squamous epithelium thickness at baseline and
after long-term exposure to STCs, so the potential of
developing STC-induced epithelial atrophy in the esophagus
as already reported in the skin35 was not excluded.
In conclusion, this trial confirmed that EoE requires
therapeutic long-term management and demonstrated that
BOT is effective and safe as maintenance therapy for adult
patients with EoE who achieved disease remission with the
same compound.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.07.039.
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Supplementary Figure 1. Consolidated Standards of Reporting Trials diagram showing the patient flow in the study. Patients
with active EoE from 29 European medical centers were screened and brought into clinicohistologic remission either via
controlled EOS-1 trial16 or via a 6-week open-label induction treatment with budesonide 1.0 mg orodispersible tablet twice
daily (BOT 1.0mg BID). After randomization, patients received double-blind (DB) treatment with either BOT 0.5 mg BID, BOT
1.0 mg BID, or placebo BID for 48 weeks. The intention-to-treat (ITT) population for efficacy and safety analyses included 204
patients and the per-protocol (PP) population for efficacy analyses consisted of 173 patients.
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Supplementary Table 1.List of International EOS-2 Study Group Institutions
Country Institution
Belgium Universitaire Ziekenhuis Leuven, Leuven
Germany Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, and Center for Esophageal
Disorders, University Hospital Hamburg-Eppendorf
II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich
Universitätsklinikum Carl Gustav Carus Technische Universität Dresden, Dresden
Israelitisches Krankenhaus in Hamburg, Hamburg
Gastroenterologische Gemeinschaftspraxis, Wiesbaden
Sana Klinikum Lichtenberg, Berlin
Universitätsklinikum des Saarlandes, Homburg, Saar
CRH Q18Clinic Siloah, Hannover
Städt. Klinikum Braunschweig GmbH, Braunschweig
Praxis für Innere Medizin und Gastroenterologie, Berlin
Otto-von-Guericke-Universitäts Klinikum Magdeburg, Magdeburg
Gastroenterologische Gemeinschaftspraxis Mainz, Mainz
Medizinisches Versorgungszentrum Dachau, Dachau
Klinikum Ludwigsburg, Ludwigsburg
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
Allgemeines Krankenhaus Celle, Celle
Klinikum Augsburg, Augsburg
The Netherlands Academic Medical Center Amsterdam, Amsterdam
St Antonius Ziekenhuis, Nieuwegein
Albert Schweizer Ziekenhuis, Dordrecht
Spain Hospital General de Tomelloso, Tomelloso, Ciudad Real, and Instituto de Investigación Sanitaria Princesa, Madrid
Hospital Universitario de la Princesa, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital de Viladecans, Barcelona
Hospital Universitario Central de Asturias, Oviedo
Hospital General du Ciudad Real, Ciudad Real
Hospital Universitario Rio Hortega, Valladolid
Agencia Sanitaria Costa del Sol, Marbella, Málaga
Switzerland Swiss EoE Research Group, Olten and University Hospital Zurich, Zurich,
University Hospital Basel, Basel
Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne,
University Hospital Zurich, Zurich
United Kingdom St George’s Hospital, London
Darlington Memorial Hospital, Darlington
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Supplementary Table 2. Q19Disease-Specific Characteristics of Study Patients Before Initial Acute Therapy for Induction of
Clinicohistologic Remission With Budesonide Orodispersible Tablets
Characteristics
BOT 0.5 mg
BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo
BID (n ¼ 68)
All patients
(n ¼ 204)
Weekly sum of daily dysphagia NRS (0–70 points),a mean ± SD 34 ± 14.8 33 ± 16.1 33 ± 15.0 33 ± 15.3
Weekly sum of daily odynophagia NRS (0–70 points),a mean ± SD 26 ± 16.1 24 ± 18.9 24 ± 16.7 25 ± 17.2
EEsAI-PRO,b mean ± SD 50 ± 16.3 52 ± 18.2 53 ± 15.3 52 ± 16.6
PatGA,c mean ± SD 6 ± 1.6 6 ± 1.7 6 ± 1.4 6 ± 1.6
Overall peak eos/mm2 hpf,d mean ± SD 277 ± 214 295 ± 237 300 ± 273 291 ± 241
Peak eos/mm2 hpf by esophageal location,d mean ± SD
Proximal 146 ± 149 194 ± 231 191 ± 266 177 ± 221
Mid 188 ± 198 190 ± 174 198 ± 197 192 ± 189
Distal 201 ± 185 211 ± 177 220 ± 164 210 ± 175
Localization of inflammation, n (%)
Proximal 57 (83.8) 56 (82.4) 61 (89.7) 174 (85.3)
Mid 57 (83.8) 60 (88.2) 64 (94.1) 181 (88.7)
Distal 65 (95.6) 62 (91.2) 66 (97.1) 193 (94.6)
Number of inflamed segments, n (%)
1 segment 7 (10.3) 7 (10.3) 3 (4.4) 17 (8.3)
2 segments 11 (16.2) 12 (17.6) 7 (10.3) 30 (14.7)
3 segments 50 (73.5) 49 (72.1) 58 (85.3) 157 (77.0)
BID, twice daily; EEsAI-PRO, Eosinophilic Esophagitis Activity Index Patient Reported Outcome; PatGA, Patient’s Global
Assessment of EoE activity.
aDaily NRS for dysphagia and odynophagia, respectively, ranging from 0 to 10 points; higher scores indicating greater
symptom severity.
bEEsAI-PRO score ranging from 0 to 100 points with higher scores indicating greater disease severity; clinical remission is
defined as a score of 20 points.
cPatGA is an NRS ranging from 0 to 10 points; higher scores indicating greater disease activity.
dPeak eosinophils count standardized to mm2 hpf (400). Peak of <16 eos/mm2 hpf in all 6 biopsies, 2 each derived from the
derived proximal, mid, and distal esophagus, was defined as histologic remission; 0 eos/mm2 hpf in all biopsies was deep
histologic remission.
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Supplementary Table 3.Protocol Prespecified Subgroup Analyses of the Primary Study End Point in Eosinophilic Esophagitis
Patients Treated With Budesonide Orodispersible Tablets or Placebo in the Double-Blind Phase
Characteristic
Patients in clinicopathologic remission at wk 48
stratified by protocol prespecified criteria, n (%)
BOT 0.5 mg
BID (n ¼ 68)
BOT 1.0 mg
BID (n ¼ 68)
Placebo BID
(n ¼ 68)
Localization of inflammation at baseline of induction treatment
Proximal esophagus
No 11/11 (100.0) 9/12 (75.0) 1/7 (14.3)
Yes 39/57 (68.4) 42/56 (75.0) 2/61 (3.3)
Middle esophagus
No 10/11 (90.9) 6/8 (75.0) 0/3 (0.0)
Yes 40/57 (70.2) 45/60 (75.0) 3/64 (4.7)
Distal esophagus
Not evaluable — 0/1 (0.0) 0/1 (0.0)
No 2/3 (66.7) 3/5 (60.0) 0/1 (0.0)
Yes 48/65 (73.8) 48/62 (77.4) 3/66 (4.5)
Extent of inflammation at baseline of induction treatment, no. of
esophageal segments affected
1 7/7 (100.0) 6/7 (85.7) 0/3 (0.0)
2 9/11 (81.8) 6/12 (50.0) 1/7 (14.3)
3 34/50 (68.0) 39/49 (79.6) 2/58 (3.4)
Concomitant use of PPIs during the double-blind phase
No 37/52 (71.2) 42/56 (75.0) 2/59 (3.4)
Yes 13/16 (81.3) 9/12 (75.0) 1/9 (11.1)
History of allergic diseases
No 9/14 (64.3) 10/13 (76.9) 1/18 (5.6)
Yes 41/54 (75.9) 41/55 (74.5) 2/50 (4.0)
Time since first symptoms
Not evaluable — — 0/2 (0.0)
Less than median (9.8 y) 21/27 (77.8) 23/33 (69.7) 2/41 (4.9)
Median or longer (9.8 y) 29/41 (70.7) 28/35 (80.0) 1/25 (4.0)
Post-hoc analyses
Baseline histology
0 eos/mm2 hpf 49/65 (75.4) 48/65 (73.8) 3/64 (4.7)
1 to 15 eos/mm2 hpf 1/3 (33.3) 3/3 (100.0) 0/2 (0.0)
BID, twice daily.
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Supplementary Table 4. Q20Post-Hoc Analyses of Endoscopic Parameters for Remitters and Nonremitters of Maintenance
Treatment of Eosinophilic Esophagitis with Orodispersible Budesonide Tablets
Outcome variablea













Total modified EREFS score (0–9
points),b mean (95% CI); n
Baseline 1 (0.6 to 1.3) 1 (0.4 to 1.1) 1 (0.6 to 1.2) 1 (0.1 to 1.3) 1 (–1.5 to 3.5) 1 (0.5 to 1.0)
EoT 1 (0.4 to 0.9) 1 (0.4 to 2.4); 15 0 (0.2 to 0.7) 2 (0.7 to 2.3); 14 1 (–1.5 to 4.2) 4 (3.5 to 4.4); 62
Absolute change from baseline
to EoT
–0 (–0.7 to 0.1) 1 (–0.2 to 1.6); 15 –0 (–0.7 to –0.2) 1 (–0.1 to 1.7); 14 0 (–1.1 to 1.8) 3 (2.7 to 3.6); 62
P value .117a .148a <001a .125a NA <.001a
Inflammatory signs subscore (0–4
points),b mean (95% CI); n
Baseline 0 (0.2 to 0.5) 0 (0.1 to 0.6) 0 (0.2 to 0.6) 0 (–0.1 to 0.3) 1 (–0.8 to 2.1) 0 (0.2 to 0.4)
EoT 0 (0.1 to 0.5) 1 (0.1 to 1.5); 15 0 (0.0 to 0.3) 1 (0.3 to 1.6); 14 1 (–1.5 to 3.5) 3 (2.3 to 2.9); 62
Absolute change from baseline
to EoT
–0 (–0.3 to 0.2) 0 (–0.3 to 1.2); 15 –0 (–0.4 to –0.1) 1 (0.1 to 1.4); 14 0 (–1.5 to 1.8) 2 (2.0 to 2.6); 62
P value .614a P ¼ .281a .004a .031a NA <.001a
Fibrotic signs subscore (0–4
points),b mean (95% CI); n
Baseline 1 (0.4 to 0.8) 0 (0.1 to 0.6) 0 (0.3 to 0.6) 1 (0.1 to 1.1) 0 (–1.1 to 1.8) 0 (0.3 to 0.6)
EoT 0 (0.2 to 0.5) 1 (0.1 to 1.1); 15 0 (0.1 to 0.4) 1 (0.1 to 1.1); 14 0 (–1.1 to 1.8) 1 (0.8 to 1.4); 62
Absolute change from baseline
to EoT
–0 (–0.4 to –0.0) 0 (–0.2 to 0.6); 15 –0 (–0.3 to –0.0) 0 (–0.4 to 0.5); 14 0 (–) 1 (0.4 to 0.9); 62
P value .025a .453a .020a 1.000a NA <.001a
NOTE. Two patients with nonassessable remission status after 48 weeks of treatment were excluded from this analysis.
BID, twice daily; NA, not applicable.
aTwo-sided Wilcoxon signed rank test for absolute change from baseline to EoT within a treatment group.
bModified EREFS grading system summing the scores of the 5 major features (edema [0–1], rings [0–3], exudates [0–2], furrows
[0–1], strictures [0–1]) and 1 minor (crêpe paper esophagus [0–1]); total score ranged from 0 to 9 points, with higher score
indicating more severe endoscopic findings. Inflammatory subscore (edema [0–1], exudates [0–2], furrows [0–1]), ranged from
0 to 4 points, with higher score indicating more severe inflammatory findings; fibrotic subscore (rings [0–3], strictures [0–1]),
ranged from 0 to 4 points, with higher score indicating more severe fibrotic findings.
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